Unique and Uniquely Successful
Authored by Christopher C. Conway, Chief Philanthropy Officer & Executive Vice President of Strategic Communications
The Indiana Biosciences Research Institute (IBRI) is a first-in-class translational medicine institute dedicated to advancing life sciences in the race to eliminate disease and improve human health and life.
By connecting early-stage biotech companies with academic researchers—and backed by the mission and resources of industry leaders, investors, and philanthropic partners—IBRI is successfully evolving a new, independent model to conquer disease, uniting previously fragmented forces in the quest for cures.
Carefully curating and supporting early-stage companies with investment, talent, and space, IBRI strategically accelerates drug discovery. Our work benefits from the relatively low cost of living and doing business here, allowing more resources to be directed toward science.
Fueled by the same entrepreneurial creativity as the groundbreaking scientific work we support, IBRI’s labs advance research across the frontiers of diabetes, metabolic disease, Alzheimer’s disease, and rare pediatric diseases. Our ambitious public-private vision cultivates talent while efficiently bridging the gap between research-driven inquiry and profit-driven drug development.
At IBRI, cures are launched on a clear pathway to clinical trials, enabled by the combined resources and experience of our academic and industry partners, without the typical pressure to deliver rapid results for commercialization. IBRI labs pursue breakthroughs that might never happen elsewhere. Breakthroughs are happening here. Our novel financing model ensures that when discoveries are ready for clinical trials, the intellectual property is sold back to industry or spun off, creating a direct stream of revenue.
By every measure, the IBRI model demonstrates a novel approach that rewards. Scientific bench work is nurtured, drug discovery is advanced, workforce development is continuous, investors see returns, and donors see impact. Most importantly, IBRI’s structure and portfolio of accomplishments matter to the patients whose lives are improved, or even saved, by this forward-looking approach to life sciences.
IBRI is driven to bring next-generation therapies to market with an understanding of the complex pressures that often bind innovation to economics. After more than a decade, the evidence is clear: IBRI is poised to transform life sciences, and for millions of people, even life itself.
